Tiger Aesthetics is pleased to announce the acquisition of Revelle Aesthetics, makers of the Avéli cellulite reduction device which is FDA cleared as a one-time treatment with long-term results. This acquisition broadens the commercial impact of the Tiger Aesthetics portfolio into the fast-growing field of regenerative body aesthetics.
Cellulite is one of the most common skin conditions worldwide, yet practitioners have struggled effectively to address the primary underlying cause. The Avéli device is the only single-use disposable device that enables visualization and targeted release of the specific septa causing the cellulite dimples. The minimally-invasive procedure is performed in-office under local anesthesia and can be administered by both licensed and trained physicians, as well as mid-level providers in many states.
Lower body rejuvenation is a rapidly growing area of unmet need amongst aesthetic consumers, with key concerns including cellulite, volume deficiency or reduction, and loose skin. With the Revelle acquisition, Tiger will be able to provide customers with a comprehensive and differentiated suite of combination options for lower body rejuvenation, inclusive of Avéli for cellulite, Viality™ for enhanced viability fat transfer, and the forthcoming alloCLAE™ and dermaCLAE™ structural adipose fillers to augment volume in aesthetic body procedures.
